

# Johan H Jendle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7672017/publications.pdf>

Version: 2024-02-01

78  
papers

2,431  
citations

257450

24  
h-index

214800

47  
g-index

82  
all docs

82  
docs citations

82  
times ranked

2387  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. <i>Journal of Diabetes Science and Technology</i> , 2023, 17, 1226-1242.	2.2	69
2	A Response to: Letter to the Editor with Regard to the Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: A Health Economic Analysis in Sweden. <i>Diabetes Therapy</i> , 2022, 13, 1125.	2.5	1
3	Analysis of Glycemic Outcomes During Real-World Hybrid Closed-Loop System Use by Individuals With Type 1 Diabetes in the United States. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210918.	2.2	0
4	Patterns and Predictors Associated With Long-Term Glycemic Control in Pediatric and Young Adult Patients with Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2022, , 193229682210964.	2.2	0
5	Screening for Diabetic Retinopathy with Extended Intervals, Safe and Without Compromising Adherence: A Retrospective Cohort Study. <i>Diabetes Therapy</i> , 2021, 12, 223-234.	2.5	6
6	Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. <i>Diabetes Therapy</i> , 2021, 12, 373-388.	2.5	30
7	Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial. <i>BMJ Open Diabetes Research and Care</i> , 2021, 9, e001971.	2.8	11
8	Real-world performance of the MiniMed 670G system in Europe. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1942-1949.	4.4	37
9	The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. <i>Diabetes Therapy</i> , 2021, 12, 2977-2991.	2.5	17
10	Cost-Effectiveness of the FreeStyle Libre System Versus Blood Glucose Self-Monitoring in Individuals with Type 2 Diabetes on Insulin Treatment in Sweden. <i>Diabetes Therapy</i> , 2021, 12, 3137-3152.	2.5	9
11	Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. <i>Cardiovascular Diabetology</i> , 2021, 20, 237.	6.8	14
12	Effectiveness of real-time continuous glucose monitoring to improve glycaemic control and pregnancy outcome in patients with gestational diabetes mellitus: a study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2020, 10, e040498.	1.9	10
13	Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. <i>Journal of Medical Economics</i> , 2020, 23, 1311-1320.	2.1	7
14	Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLeCT Prospective, Observational Study. <i>Diabetes Therapy</i> , 2020, 11, 2159-2167.	2.5	2
15	Costs of diabetes complications: hospital-based care and absence from work for 392,200 people with type 2 diabetes and matched control participants in Sweden. <i>Diabetologia</i> , 2020, 63, 2582-2594.	6.3	47
16	Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 845-854.	11.4	46
17	The Use of eHealth for the Care of Patients With Diabetes in Connection to the COVID-19 Pandemic. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 739-740.	2.2	7
18	Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1586-1597.	4.4	15

#	ARTICLE	IF	CITATIONS
19	Continuous Glucose Monitoring Diving and Diabetes: An Update of the Swedish Recommendations. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 170-173.	2.2	7
20	975-P: Effect of Late Bolus Injections on Glycemic Variability Studied by Connected Pens. <i>Diabetes</i> , 2020, 69, .	0.6	3
21	Recreational diving in persons with type 1 and type 2 diabetes: Advancing capabilities and recommendations. <i>Diving and Hyperbaric Medicine</i> , 2020, 50, 135-143.	0.5	3
22	Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5977-5990.	3.6	19
23	Carbohydrate Loading Followed by High Carbohydrate Intake During Prolonged Physical Exercise and Its Impact on Glucose Control in Individuals With Diabetes Type 1â€”An Exploratory Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 571.	3.5	11
24	Improved treatment satisfaction in patients with type 2 diabetes treated with onceâ€”weekly semaglutide in the SUSTAIN trials. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2315-2326.	4.4	13
25	Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment, both in combination with metformin: A randomized, open, parallelâ€”group study. <i>Endocrinology, Diabetes and Metabolism</i> , 2019, 2, e00058.	2.4	8
26	Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 110-118.	4.4	39
27	Editorial: Physical Activity and Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , 2019, 10, 860.	3.5	6
28	Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study. <i>Journal of the American Society of Hypertension</i> , 2018, 12, 346-355.	2.3	5
29	Achieving Good Glycemic Control Early After Onset of Diabetes: A Cost-Effectiveness Analysis in Patients with Type 1 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2018, 9, 87-99.	2.5	4
30	Real-Time Continuous Glucose Monitoring Usage in Pilots with Diabetes: An Option to Improve Safety. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 453-454.	4.4	3
31	A utility valuation study assessing the impact of postprandial glucose control on quality of life of individuals with type 1 or type 2 diabetes. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 20.	1.9	2
32	Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2017, 8, 1015-1030.	2.5	12
33	Effects on Subclinical Heart Failure in Type 2 Diabetic Subjects on Liraglutide Treatment vs. Glimepiride Both in Combination with Metformin: A Randomized Open Parallel-Group Study. <i>Frontiers in Endocrinology</i> , 2017, 8, 325.	3.5	17
34	Pilots and Diabetes Technology. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 191-194.	2.2	2
35	Continuous glucose monitoring in patients with type 2 diabetes treated with glucagonâ€”like peptideâ€”1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARDâ€”4 substudy. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 999-1005.	4.4	37
36	Insulin Pumps. <i>Diabetes Technology and Therapeutics</i> , 2016, 18, S-22-S-28.	4.4	0

#	ARTICLE	IF	CITATIONS
37	Indications for Insulin Pump Therapy in Type 1 Diabetes and Associations With Glycemic Control. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1027-1033.	2.2	15
38	Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 776-790.	4.0	105
39	Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 13.	2.4	24
40	Quantifying The Short-Term Impact of Changes In Hba1c, Weight And Insulin Regimen on Health Related Quality-of-Life. <i>Value in Health</i> , 2015, 18, A616.	0.3	2
41	Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study. <i>Lancet</i> , The, 2015, 385, 2057-2066.	13.7	180
42	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	2.7	88
43	Healthâ€economic analysis of realâ€time continuous glucose monitoring in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2015, 32, 618-626.	2.3	34
44	Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18 168 people with type 1 diabetes: observational study. <i>BMJ</i> , The, 2015, 350, h3234-h3234.	6.0	193
45	Evaluation of glucose control when a new strategy of increased carbohydrate supply is implemented during prolonged physical exercise in type 1 diabetes. <i>European Journal of Applied Physiology</i> , 2015, 115, 2599-2607.	2.5	33
46	Glucose Changes and Working Memory in Individuals with Type 1 Diabetes During Air Pressure Changes Simulating Skydiving. <i>Diabetes Technology and Therapeutics</i> , 2014, 16, 56-62.	4.4	3
47	Sialic acid and incidence of hospitalization for diabetes and its complications during 40-years of follow-up in a large cohort: The VÄrmland survey. <i>Primary Care Diabetes</i> , 2014, 8, 352-357.	1.8	15
48	Insulin degludec improves healthâ€related quality of life (SFâ€36 Â®) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a metaâ€analysis of phase 3a trials. <i>Diabetic Medicine</i> , 2013, 30, 226-232.	2.3	32
49	New Insulins and Insulin Therapy. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, S-40-S-47.	4.4	3
50	Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results. <i>Journal of Medical Economics</i> , 2012, 15, 1-5.	2.1	20
51	<i>In-Vitro</i> Performance of the Enlite Sensor in Various Glucose Concentrations during Hypobaric and Hyperbaric Conditions. <i>Journal of Diabetes Science and Technology</i> , 2012, 6, 1375-1382.	2.2	10
52	Combined effects of brachial pulse pressure and sialic acid for risk of cardiovascular events during 40 years of follow-up in 37â€843 individuals. <i>Journal of Hypertension</i> , 2012, 30, 1718-1724.	0.5	12
53	Lateâ€onset familial neurohypophyseal diabetes insipidus due to a novel mutation in the AVP gene. <i>Clinical Endocrinology</i> , 2012, 77, 586-592.	2.4	11
54	Insulin and GLP-1 analog combinations in type 2 diabetes mellitus: a critical review. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 1463-1474.	4.1	12

#	ARTICLE	IF	CITATIONS
55	Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. <i>Primary Care Diabetes</i> , 2012, 6, 41-46.	1.8	65
56	Willingness-to-pay for benefits associated with basal insulin treatment of type 2 diabetes. <i>Journal of Medical Economics</i> , 2012, 15, 261-263.	2.1	5
57	Continuous Glucose Monitoring—A Study of the Enlite Sensor During Hypo- and Hyperbaric Conditions. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 527-532.	4.4	19
58	Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. <i>Diabetic Medicine</i> , 2012, 29, 303-312.	2.3	13
59	Improved health status with insulin degludec compared with insulin glargine in people with Type 1 diabetes. <i>Diabetic Medicine</i> , 2012, 29, 716-720.	2.3	31
60	Swedish recommendations on recreational diving and diabetes mellitus. <i>Diving and Hyperbaric Medicine</i> , 2012, 42, 231-3.	0.5	5
61	Impact of High Altitudes on Glucose Control. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 1621-1622.	2.2	5
62	Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. <i>Diabetes Care</i> , 2011, 34, 661-665.	8.6	156
63	Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2010, 26, 917-923.	1.9	53
64	Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long-term follow-up study. <i>Diabetes and Metabolism</i> , 2010, 36, 137-143.	2.9	22
65	Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus. <i>Scandinavian Journal of Urology and Nephrology</i> , 2010, 44, 324-330.	1.4	17
66	Accuracy and Reliability of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes During Recreational Diving. <i>Diabetes Technology and Therapeutics</i> , 2009, 11, 493-497.	4.4	22
67	Resource utilisation and costs for the treatment of diabetes in the developed world: an economical burden that needs to be solved. <i>International Journal of Clinical Practice</i> , 2009, 63, 980-982.	1.7	8
68	Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 1163-1172.	4.4	247
69	Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naïve type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. <i>International Journal of Clinical Practice</i> , 2008, 62, 869-876.	1.7	14
70	The Benefits of Continuous Glucose Monitoring and a Glucose Monitoring Schedule in Individuals with Type 1 Diabetes during Recreational Diving. <i>Journal of Diabetes Science and Technology</i> , 2008, 2, 778-784.	2.2	21
71	Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. <i>Diabetic Medicine</i> , 2006, 23, 729-735.	2.3	108
72	The Impact of Smoking on Inhaled Insulin. <i>Diabetes Care</i> , 2003, 26, 677-682.	8.6	118

#	ARTICLE	IF	CITATIONS
73	Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. <i>Diabetologia</i> , 2001, 44, 305-308.	6.3	100
74	Intrapulmonary administration of insulin to healthy volunteers. <i>Journal of Internal Medicine</i> , 1996, 240, 93-98.	6.0	36
75	Effects of intrapulmonary insulin in patients with non-insulin-dependent diabetes. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1996, 56, 555-561.	1.2	25
76	An exploration of intrapulmonary insulin administration in anaesthetized and mechanically ventilated pigs. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1996, 56, 251-258.	1.2	8
77	Delivery and Retention of an Insulin Aerosol Produced by a New Jet Nebulizer. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 1995, 8, 243-254.	1.2	13
78	Subpopulations of variants resistant to imipenem in <i>Pseudomonas aeruginosa</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 22, 643-649.	3.0	8